R. T. Clarke and C. Mitchell, Haemolytic uraemic syndrome in a patient with acute lymphoblastic leukaemia, Pediatric Blood & Cancer, vol.55, pp.1402-1405, 2010.

M. A. Elliott, L. Letendre, D. A. Gastineau, J. L. Winters, R. K. Pruthi et al., Cancer-associated microangiopathic hemolytic anemia with thrombocytopenia: an important diagnostic consideration, European Journal of Haematology, vol.85, pp.43-50, 2010.

V. Fremeaux-bacchi, F. Fakhouri, A. Garnier, F. Bienaime, M. A. Dragon-durey et al., Genetics and outcome of atypical hemolytic uremic syndrome: a nationwide French series comparing children and adults, Clinical Journal of the American Society of Nephrology, vol.8, pp.554-562, 2013.

K. Lechner and H. L. Obermeier, Cancerrelated microangiopathic hemolytic anemia: clinical and laboratory features in 168 reported cases, Medicine, vol.91, pp.195-205, 2012.

C. M. Legendre, C. Licht, P. Muus, L. A. Greenbaum, S. Babu et al., Terminal complement inhibitor eculizumab in atypical hemolytic-uremic syndrome, New England Journal of Medicine, vol.368, pp.2169-2181, 2013.

J. Menne, M. Nitschke, R. Stingele, M. Abu-tair, J. Beneke et al., British Medical Journal, vol.345, p.4565, 2012.

M. Noris, J. Caprioli, E. Bresin, C. Mossali, G. Pianetti et al., Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype, Clinical Journal of the American Society of Nephrology, vol.5, pp.1844-1859, 2010.

R. Peffault-de-latour, A. Xhaard, V. Fremeaux-bacchi, P. Coppo, A. M. Fischer et al., Successful use of eculizumab in a patient with post-transplant thrombotic microangiopathy, British Journal of Haematology, vol.161, pp.279-280, 2013.

I. Shapira, D. Andrade, S. L. Allen, and J. E. Salmon, Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab, Arthritis and Rheumatism, vol.64, pp.2719-2723, 2012.

J. Zuber, F. Fakhouri, L. T. Roumenina, C. Loirat, and V. Fremeaux-bacchi, Use of eculizumab for atypical haemolytic uraemic syndrome and C3 glomerulopathies, Nature Reviews. Nephrology, vol.8, pp.643-657, 2013.